Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas


Ozkaya H. M. , Sahin S., Korkmaz O. P. , Durcan E. , Sahin H. R. , Celik E. , ...Daha Fazla

GROWTH HORMONE & IGF RESEARCH, cilt.55, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.ghir.2020.101356
  • Dergi Adı: GROWTH HORMONE & IGF RESEARCH

Özet

Objective: To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).